Upcoming Webinar | July 22, 2026 | 11:00 am EDT / 5:00 pm CEST

Building Translational Cardiometabolic Models: Integrating Diet Conditioning and Genetics

About the webinar:

Obesity and its related comorbidities, including MASH, cardiovascular disease, and metabolic dysfunction are rapidly evolving areas of drug development, driven by increasingly complex therapeutic approaches. As these therapies advance, traditional single-model strategies are often insufficient to fully capture disease biology or generate translatable insights.

In this webinar, Laura Griffin, Associate Director of Cardiometabolic Portfolio at Taconic Biosciences, presents a practical framework for building more clinically relevant preclinical studies by integrating diet conditioning, genetic models, and study design.

Key topics include:

Establishing study-ready disease states through controlled diet conditioning and cohort standardization
Leveraging genetically engineered models, including humanized GLP-1 receptor models, to better align with therapeutic targets
Designing integrated cohort design strategies that combine genetics, diet, and phenotype monitoring

In addition to focusing on individual models, this session highlights how to assemble the right combination of tools to better reflect human disease and support more confident decision-making in cardiometabolic research.

Cardiometabolic Diseases Portfolio

Explore Taconic's cardiometabolic disease portfolio, including validated mouse models for obesity, MASH, diabetes, and dyslipidemia.

Explore Now

Why Taconic?

Taconic Biosciences is a global leader in genetically engineered mouse models and colony management services. We support researchers in advancing their science with innovative, reliable solutions.

Learn More about our Fully Integrated Custom Model Generation and Colony Management Solutions.

Secure Your Spot

Meet the Team

Speaker:

Laura Griffin, PhD

Associate Director, Cardiometabolic Portfolio | Taconic Biosciences

Laura Griffin, PhD, is the Associate Director of the Cardiometabolic Disease Portfolio at Taconic Biosciences, where she leads strategy and scientific positioning for models and services supporting CVMD research. She works closely with pharmaceutical and biotech researchers to design translational preclinical approaches that integrate genetic models, diet conditioning, and study design. Dr. Griffin has over a decade of experience in preclinical research and model application, with expertise in disease modeling and experimental strategy. She has contributed to the development and positioning of key cardiometabolic platforms, including diet-induced obesity systems and humanized receptor models. Her work focuses on helping researchers build study-ready systems that improve reproducibility and better reflect human disease.

Moderator:

Philip Dubé, PhD

Director, Scientific Marketing | Taconic Biosciences

Dr. Philip Dubé is the Director of Scientific Marketing at Taconic Biosciences with over 18 years of experience in rodent model use. He specializes in mouse models for immunology, oncology, immuno-oncology, and inflammatory bowel disease (IBD). Dr. Dubé earned his Ph.D. in physiology and an Honors B.Sc. in pharmacology from the University of Toronto. He completed postdoctoral fellowships in IBD research at Vanderbilt University and Children’s Hospital Los Angeles and has served as an Institutional Animal Care and Use Committee member.